Utilizing micro-RNA-371a-3p for recurrence prediction in clinical stage I testicular cancerx
Open Access
- 8 July 2026
- journal article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (8)
Abstract
No abstract availableFunding Information
- Cancer Center Program (P30 CA008748)
This publication has 13 references indexed in Scilit:
- Clinical utility of tumour‐informed circulating tumour DNA in patients with testicular cancerBJU International, 2025
- Testicular Germ Cell TumorsJAMA, 2025
- Comparison of serum and plasma microRNA expression levels in patients with germ cell tumoursBJU International, 2025
- Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 StudyClinical Cancer Research, 2023
- Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines OfficeEuropean Urology Oncology, 2023
- Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell CancerEuropean Urology Oncology, 2021
- Trends in Cancer Incidence in US Adolescents and Young Adults, 1973-2015JAMA Network Open, 2020
- Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active SurveillanceJournal of Clinical Oncology, 2015
- Surveillance for Stage I Nonseminoma Testicular Cancer: Outcomes and Long-Term Follow-Up in a Population-Based CohortJournal of Clinical Oncology, 2014
- Medical Treatment of Advanced Testicular CancerJAMA, 2008